Hepatocellular Carcinoma; Clinical Trial
Official title:
The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related Gene
| Verified date | March 2016 |
| Source | Eastern Hepatobiliary Surgery Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | China: Ministry of Health |
| Study type | Observational |
Recurrence and metastasis are the main factors affecting the prognosis of liver cancer after
curative resection. Establishing an effective prognostic evaluation method is able to not
only assess patients' prognosis but also guide the treatment. At the same time, it helps us
to gain knowledge of the mechanism underlying recurrence and metastasis of liver cancer and
to provide the basis for the search for new effective intervention method.
In order to establish an effective prognostic evaluation method, we select liver cancer
patients undergoing curative resection in our hospital. We plan to employ various
technologies such as gene chip, methylation chip and flow cytometry to carry out
comprehensive researches on liver cancer cell genetics, epigenetics, stem cells and tumor
microenvironment changes. By analyzing clinical information including pathological features,
patients' response to treatment, relapse, metastasis and survival, we aim to obtain the
important factors affecting liver cancer prognosis, survival, recurrence and metastasis in
order to be able to find and establish the effective prognostic evaluation method.
| Status | Completed |
| Enrollment | 300 |
| Est. completion date | December 2015 |
| Est. primary completion date | December 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 70 Years |
| Eligibility |
Inclusion Criteria: 1. Patients with radical hepatectomy in Eastern Hepatobiliary Surgery Hospital; 2. Hepatocellular carcinoma confirmed pathologically; 3. The liver function is Child-Pugh A, as well as the Child-Pugh B achieved to A after treatment; 4. The HAI score of cirrhosis <12 Exclusion Criteria: 1. Patients with apparent cardiac, pulmonary, cerebric and renal dysfunction,which may affect the treatment of liver cancer. 2. Patients with other diseases which may affect the treatment mentioned here. 3. Patients with medical history of other malignant tumors. |
Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| China | Eastern Hepatobiliary Surgery Hospital | Shanghai | Shanghai |
| China | Eastern hepatobilliary surgery hospital | Shanghai | Shanghai |
| Lead Sponsor | Collaborator |
|---|---|
| Eastern Hepatobiliary Surgery Hospital |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Overall survival | 2015 | Yes |